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Abstract
Background:  Glutathione (GSH) plays an important role in anti-oxidant defense and
detoxification reactions. It is primarily synthesized in the liver by the transsulfuration pathway and
exported to provide precursors for in situ GSH synthesis by other tissues. Deficits in glutathione
have been implicated in aging and a host of diseases including Alzheimer's disease, Parkinson's
disease, cardiovascular disease, cancer, Down syndrome and autism.
Approach: We explore the properties of glutathione metabolism in the liver by experimenting
with a mathematical model of one-carbon metabolism, the transsulfuration pathway, and
glutathione synthesis, transport, and breakdown. The model is based on known properties of the
enzymes and the regulation of those enzymes by oxidative stress. We explore the half-life of
glutathione, the regulation of glutathione synthesis, and its sensitivity to fluctuations in amino acid
input. We use the model to simulate the metabolic profiles previously observed in Down syndrome
and autism and compare the model results to clinical data.
Conclusion: We show that the glutathione pools in hepatic cells and in the blood are quite
insensitive to fluctuations in amino acid input and offer an explanation based on model predictions.
In contrast, we show that hepatic glutathione pools are highly sensitive to the level of oxidative
stress. The model shows that overexpression of genes on chromosome 21 and an increase in
oxidative stress can explain the metabolic profile of Down syndrome. The model also correctly
simulates the metabolic profile of autism when oxidative stress is substantially increased and the
adenosine concentration is raised. Finally, we discuss how individual variation arises and its
consequences for one-carbon and glutathione metabolism.
Background
Glutathione is a low molecular weight tri-peptide (γ-
glutamyl-cysteinyl-glycine) found at relatively high con-
centrations (0.5–10 mM) in all mammalian cells and rel-
atively low concentrations (2–20 μM) in plasma [1].
Inside cells, most of the glutathione (85–90%) is in the
cytosol where it primarily exists in a reduced form (GSH)
and to a much lesser extent as an oxidized disulfide form
(GSSG). The high GSH/GSSG ratio provides the essential
reducing environment inside the cell. GSH is manufac-
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tured in the cytosol by a two-step process: the first step,
which combines cysteine and glutamate, is catalyzed by γ-
glutamylcysteine synthetase (GCS); the second step,
which adds the glycine residue, is catalyzed by glutathione
synthetase (GS). Glycine and glutamate are produced and
used by many metabolic reactions and have relatively
high cytosolic concentrations. Cytosolic cysteine is the
limiting amino acid for GSH synthesis because it has a low
concentration compared to glycine and glutamate.
Cytosolic cysteine comes from only three sources: (1)
from methionine via the methionine cycle and the trans-
sulfuration pathway, (2) direct import into the cell from
the plasma, and (3) from excess protein catabolism over
protein synthesis. Thus the availability of cysteine and the
activity of GCS are the major determinants of GSH synthe-
sis. The enzyme cystathionine-β-synthase (CBS) that cata-
lyzes the first step in the transsulfuration pathway is
highly expressed in liver cells but not highly expressed in
peripheral cells, so it is not surprising that the liver is the
major producer of GSH, much of which is exported to the
plasma and enzymatically broken down to cysteinylgly-
cine and cyst(e)ine that is subsequently taken up by other
cells for GSH synthesis.
Glutathione is involved in many pathways that are essen-
tial for normal intracellular homeostasis. It detoxifies
xenobiotics and heavy metals through a reaction catalyzed
by GSH S-transferases that bind them to the sulfhydryl
group on the cysteine residue. GSH plays a role in regulat-
ing lipid, glucose, and amino acid metabolism because it
is necessary for the hepatic response to insulin-sensitizing
agents [2]. GSH is necessary for the interconversion of
prostaglandins [3]. The removal of formaldehyde, a car-
cinogen and a product of one-carbon metabolism,
requires glutathione, and glutathione is involved in T-
lymphocyte activation and viral resistance [4]. Finally,
glutathione scavenges reactive oxygen species including
superoxide and hydrogen peroxide. In these reactions
GSH is oxidized to GSSG and the ratio [GSH]/[GSSG], an
indicator of the redox status of the cell, is known to regu-
late redox sensitive enzymes in the pathways for cell pro-
liferation and cell apoptosis [5]. Thus, it is not surprising
that GSH (or the [GSH]/[GSSG] ratio) plays a key role in
many diseases including cancer, inflammation, Alzhe-
imer's disease, Parkinson's disease, sickle cell anemia,
liver disease, cystic fibrosis, AIDS, heart attack, stroke, and
diabetes [4,6] as well as in aging [7-9]. Reactive oxygen
species also cause birth defects in rats, which are pre-
vented by administration of GSH [10]. For more on glu-
tathione chemistry and health effects, see [1,4,11-15].
During the past several years we have created mathemati-
cal models for different parts of one-carbon metabolism
[16-21]. The purpose of the modeling was to answer ques-
tions posed by experiments or experimentalists and to
investigate mechanisms of regulation in one-carbon
metabolism. In this paper, we extend our most recent
model [20] to include cysteine and glutathione metabo-
lism (Figure 1). Since this mathematical model is quite
complicated, it is useful to be clear why our model needs
to include all of one carbon metabolism and not just the
transsulfuration pathway. First, methionine is a major
hepatic source of cysteine through the methionine cycle
and the transsulfuration pathway. Secondly, the redox sta-
tus of the cell affects many of the enzymes in one-carbon
metabolism including MATI, MATIII, MS, BHMT, as well
as CBS and GCS in the transsulfuration pathway, and
therefore one cannot evaluate GSH metabolism without
including the methionine and folate cycles. Thirdly,
patients with Down syndrome or autism have increased
oxidative stress and exhibit particular disturbed profiles of
one-carbon metabolism [13-15]. We would like to under-
stand how oxidative stress (and the chromosome 21 tri-
somy in the case of Down syndrome) could create these
disturbed profiles.
Model Overview
Figure 1 shows the biochemical pathways in the hepatic
cellular model used in this paper. Rectangular boxes rep-
resent the substrates that can vary in the model, and the
ellipses contain the acronyms of the enzymes that catalyze
particular reactions. There is one differential equation for
each substrate that says that the rate of change of the con-
centration of the substrate is the sum of the reaction veloc-
ities (μM/hr) that produce it minus the sum of the
reaction velocities that use it. Full names for all the
enzymes and substrates are given in Additional File 1.
Non-boxed substrates are taken to be constant or indicate
products of reactions. This model extends the model for
one carbon metabolism in [20] by adding the transsulfu-
ration pathway, the synthesis of glutathione, and its trans-
port into the blood. Here we discuss the main ideas
involved in modeling the transsulfuration pathway, refer-
ring the reader to [20] (and its online supplementary
material) for a discussion of the other parts of the model.
A complete description of the full mathematical model
and the values of all parameters are given in the online
Additional File 1.
One of the most interesting features of one carbon metab-
olism is that reaction velocities are often affected not just
by substrate and product concentrations and enzyme
activities but also by the concentrations of substrates in
distant parts of the reaction network that act as allosteric
activators or inhibitors of the enzyme. As a result, the for-
mulas for reaction velocities are often complicated func-
tions of many variables. This is well illustrated by the
velocity equation for the CBS reaction, the first step in the
transsulfuration pathway:Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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The first factor is simply Michaelis-Menten kinetics for the
CBS reaction that uses homocysteine (Hcy) and serine
(Ser) as substrates. We take the Michaelis constants from
the literature. The second term is the activation of CBS by
SAM and SAH that was discovered by Finkelstein and Mar-
tin [22]. The form of the activation was derived by nonlin-
ear regression on the data in [23,24]. The constant C is
chosen so that the second term equals one in the normal
steady state (see below). The last term is the activation of
CBS by oxidative stress [25,26], which is represented by
the concentration of H2O2.
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One-carbon metabolism and the transsulfuration pathway Figure 1
One-carbon metabolism and the transsulfuration pathway. Rectangles enclose the names or acronyms of substrates 
that are variables in the model. Substrates not in rectangles are held constant or are the products of reactions that we do not 
keep track of. Arrows at the bottom of the figure represent import from the gut and other cells, and losses to other cells and 
to degradation. There is one differential equation for each substrate. The ellipses contain the acronyms of the enzymes that 
catalyze the reactions. Full names for all the enzymes and substrates, as well as a complete description of the mathematical 
model and the values of all parameters are given in the online Additional File 1.Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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The differential equation for the concentration of
cytosolic cysteine (Cys) is straightforward:
The first term on the right is the production of cysteine
from cystathionine (Cysta) by CGTL and the second term
is the import of cysteine into the cell, which depends on
the concentration of cysteine in the blood ([bCys]). The
third term is the loss of cysteine in the reaction catalyzed
by GCS that makes glutamyl-cysteine and the fourth term
represents the loss of cysteine to other pathways (for
example to sulfate and taurine). Cysteine also used for
protein synthesis and is produced by protein catabolism;
in the model we assume that these two rates balance. The
form for the fourth term was chosen because the data in
[27] indicate that at normal cysteine concentrations
(approximately 200 μM) most of the flux away from
cysteine is toward GSH and only a moderate amount
towards other pathways. However, as [Cys] rises an
increasing fraction is sent towards the synthesis of taurine.
Formulas for VCGTL and VbCYSc (the transport of cysteine
into the cell from the blood) appear in Additional File 1.
The first step in the synthesis of GSH is the formation of
γ-glutamyl-cysteine (GluCys) from the constituent amino
acids glutamate and cysteine by the enzyme γ-glutamyl-
cysteine synthetase (GCS, also called glutamate cysteine
ligase (GCL)). The reaction is reversible and GSH is a com-
petitive inhibitor of GCS against glutamate [28-30].
The third factor in the following formula is the activation
of GCS by H2O2 [25,26].
The second step in the synthesis of GSH is the addition of
the glycine residue to GluCys by the enzyme glutathione
synthase (GS). We follow [30,31] and use a reversible bi-
reactant Michaelis-Menten mechanism.
The differential equation for cytosolic GSH is:
The first term is the synthesis of GSH from glycine and
glutamyl-cysteine. The second term is the transport of
GSH out of the liver cell into the blood. Vgsh_out is actually
the sum of two terms, one for the high affinity transporter
and one for the low affinity transporter [32]. We ignore
the canalicular transport into the bile because it is a rela-
tively small percentage of total export [33]. The third term
is the rate of production of oxidized GSSG from GSH via
the enzyme GPX and the fourth term is the conversion of
GSSG back to GSH via the enzyme GR. We ignore other
reactive oxygen species besides H2O2, or, put a different
way, H2O2 represents them all. The number two occurs in
both these terms because two molecules of GSH combine
to make one GSSG. In the fifth term we are assuming that
0.2% of the GSH is removed each hour in detoxification
reactions that form conjugates [12].
The kinetics of sinusoidal efflux of GSH has been well
studied in the perfused rat liver. The major part of the flux
is carried by the low affinity transporter, which has sig-
moidal kinetics with a Vmax in the range 900–1400 μM/hr,
a Km of approximately 3000 μM, and a Hill coefficient of
approximately 3 [34-36]. In our model we use a Vmax of
1100 μM/hr, a Km of 3000 μM, and a Hill coefficient of 3.
We use standard Michaelis-Menten kinetics for the high
affinity GSH transporter and for the two GSSG transport-
ers.
We track five variables in the blood, [GSH], [GSSG], [Gly],
[Cys] and [Glut]. Glycine, glutamate, and cysteine enter
blood from intestinal absorption at rates that we vary in
various experiments with the model; the normal rates are
630 μM/hr, 273 μM/hr and 70 μM/hr, respectively. We
assume for convenience that the volume of the blood is
the same as the volume of the liver. Glycine, cysteine, and
glutamate leave the blood by transport into liver cells
(depending on their concentrations) and they are also
formed in the blood by the breakdown of GSH and GSSG
into their component amino acids [37,38]. We also
assume that normally 10% of the cysteine, glycine, and
glutamate, in the blood is taken up per hour by other cells
and that an additional 25% of cysteine is converted to cys-
tine. Under normal conditions a large percentage of blood
GSH and GSSG is broken down into the component
amino acids and a small amount is taken up by other cells
or otherwise leaves the system. As above, full details and
formulas appear in Addition File 1.
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For each in silico computation, the values of various con-
stants (like H2O2) are given, as are the methionine and
serine levels in the blood, and the rates of input of
cysteine glutamate, and glycine into the blood. These are
the "inputs" to the model. The differential equations are
then solved to determine the steady-state values of the
concentrations of all the variables and the steady state
rates of all the reactions. Of course, if the inputs are differ-
ent the steady state will be different. We experiment with
the model by changing the inputs or changing parameters
(for example, a parameter that gives the strength of a par-
ticular allosteric interaction) and determine what the
effect is. By removing interactions we can take the model
apart piece by piece so that we can understand how and
why glutathione metabolism works the way it does. We
also allow the inputs to vary as functions of time (for
example the amino acid input will vary because of meals)
and compute the time course of each concentration and
reaction rate. This allows us to investigate the homeostatic
mechanisms that protect the system against fluctuations
in the inputs.
A number of substrate concentrations are fixed in the
model and in all the simulations reported below. These
include: cytosolic GAR (10), NADPH (50), betaine (50),
formaldehyde (500), dUMP (20), and total cellular folate
(20). All concentrations are in μM.
Limitations of the model
This model was designed to allow us to study various reg-
ulatory mechanisms in the transsulfuration pathway and
the effects of oxidative stress, particularly as applied to
Down syndrome and autism. No mathematical model
can track all of the variables that might affect a complex
biochemical system such as glutathione metabolism. This
is also true, of course, in biological experimentation. This
model is no exception. We ignore canalicular excretion of
GSH. We use Km values in the ranges determined experi-
mentally but there is much less information on Vmax val-
ues. Often we choose Vmax values so that the steady state
concentrations of substrates and products lie within the
normal published ranges. Cellular amino acid concentra-
tions are increased by feeding and protein degradation
and decreased by protein synthesis, growth and use in
one-carbon metabolism. In this model we assume that
protein synthesis and degradation are in balance and that
no amino acids are used for growth. The consequences of
this assumption are outlined in the discussion.
One-carbon metabolism and the transsulfuration path-
way contain many allosteric interactions by which sub-
strates in one part of the pathway affect the activity of
distant enzymes. We use experimentally determined
forms for these allosteric interactions but sometimes the
details of the kinetics are not known, forcing us to make
reasonable educated guesses. Similarly, many effects of
oxidative stress on the enzymes of one carbon metabo-
lism and the transsulfuration pathways are known but
detailed kinetics are not available.
In this paper we are mainly interested in intracellular liver
metabolism, so we take a somewhat simple view of the
fates glutathione and its metabolites in the blood. Future
work will include a more detailed model of the blood
compartment and inter-organ regulation of glutathione
and its component amino acids. Thus, we do not expect
that our model will make perfect quantitative predictions.
Rather, we want to use it to investigate the qualitative fea-
tures of glutathione metabolism in the normal state and
in various disease states.
Results
A. Normal model steady-state concentrations and 
velocities
We take the normal values of inputs to be the following.
Blood methionine is 30 μM and blood serine is 150 μM.
The rates of cysteine, glycine, and glutamate input to the
blood are 70 μM/hr, 630 μM/hr, and 273 μM/hr respec-
tively. The normal concentration of H2O2 is 0.01 μM.
With these inputs, the model computes the concentra-
tions of the cytosolic variables given in Table 1.
These model values correspond well to the values in the
literature. For cytosolic folate variables and methionine
cycle variables, see the discussions in our previous papers
[16-21]. Typical values of GSH in animal cells are in the
range 500–10,000 μM or 0.5–10 mM [1,39]. Typical val-
ues for cysteine are 150–250 μM [1] and for cystathionine
Table 1: Normal model cytosolic concentrations (μM)
Folates Methionine cycle Transsulfuration Other
THF = 4.61 Met = 49.2 Cysta = 36.9 Ser = 563
510CH = 0.28 SAM = 81.1 Cys = 195 Gly = 924
510CH2 = 0.51 SAH = 19.1 GluCys = 9.8 Sarc = 9.16
10fTHF = 3.41 Hcy = 1.12 GSH = 6591 DMG = 0.71
5mTHF = 4.50 GSSG = 61.3 Aicart = 0.94
DHF = 0.039 Glut = 3219 HCOOH = 13.1Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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40 μM [40]. The ratio [GSH]/[GSSG] is thought to be
around 100 for cells that are not under oxidative stress
[41], and [GSH]/[GSSG] = 107.5 in our model cell.
The computed velocities of the cytosolic reactions are
given in Table 2. There is very little information in the lit-
erature about reaction velocities because they are difficult
to measure. However, the model concentration of GSH
declines in the fasting state about as rapidly as observed
experimentally (See Section B, below). This indicates that
the overall rates of GSH production from cysteine and
methionine and the transport of GSH out of the cell are in
the appropriate ranges. We also note that the flux around
the methionine cycle is 205 μM/hr and approximately
half enters the transsulfuration pathway (VCBS = 103 μM/
hr) and half is remethylated to methionine in accordance
with the results of Finkelstein and Martin [22].
The computed concentrations of variables in the blood
are given in Table 3. Wu et al. report that the combined
cysteine and cystine concentrations are 110–325 μM [1].
In our model the computed plasma cysteine concentra-
tion is 186 μM, which is in the middle of this range.
Plasma concentrations in humans are reported in the
range 2–20 μM for GSH [1,13,14], and 0.14–0.34 μM for
GSSG [13,14,42]. The average plasma GSH/GSSG ratio is
reported to be in the range 25–28 μM with a large stand-
ard deviation [14,15], and in the model it is 26.5. Plasma
glycine levels are reported to be approximately 300 μM in
[43].
The computed values of various transport rates are given
in Table 4. We use the abbreviations o = outside, b =
blood, c = cytosol, so, for example, VoCysb is the transport
of cysteine from the outside into the blood. VoCysb, VoGlyb,
and VoGlutb are inputs to the model. All other transport
velocities are computed by the model. The second row
shows the transport velocities of the five amino acids in
the model from the blood into liver cells. The third row
shows the transport velocities of GSH and GSSG from the
cell into the blood. Detailed kinetic information is availa-
ble on amino acid transporters [44,45] and on the high
and low affinity transporters of GSH and GSSG [32,39,46]
and we chose our kinetics parameters from this literature.
The fourth row in Table 4 requires more comment. Our
main interest is to understand the synthesis and export of
GSH in liver cells and how intracellular metabolite bal-
ance is affected by oxidative stress. Since GSH is exported
rapidly from liver cells and much of the export is broken
down into the constituent amino acids that are then reim-
ported into liver cells, it was necessary to include the
blood compartment in our model. The blood communi-
cates with all other tissues none of which are in our
model. We have therefore necessarily made a number of
assumptions about the loss of GSH, GSSG, Cys, Gly, and
Glu to other tissues. For example, as discussed above, we
assume that normally 10% per hour of the cysteine, gly-
cine, and glutamate in the blood is taken up by other cells
and that an additional 25% of cysteine in the blood is lost
by conversion to cystine. The velocities in the fourth row
reflect these assumptions.
B. The Half-life of Glutathione
Ookhtens et al. [34] reported that when buthionine sul-
foximine is used to inhibit the activity of GCS (which cat-
alyzes the first step in GSH synthesis) a half life of 2–6
hours for cellular GSH is observed. This is consistent with
the experiments of [47]. Moreover, the rate of sinusoidal
GSH efflux in both fed and starved rats is near saturation
at about 80% of Vmax, about 1000–1200 μM/h [34].
Thus, if the cytosolic GSH concentration is approximately
7000 μM, then the half life would be in the 2–3 hour
range. Therefore, a variety of experimental studies and cal-
culations consistently suggest a short half life in the 2–3
hour range.
By contrast, Aw et al. [33] report that rats fasted for 48
hours lose approximately 44% of the intracellular GSH in
their hepatocytes. They also report that after 48 hours the
rate of GSH transport out of the cell declined by 38%.
These results are consistent with Tateishi et al. [48,49]
who reported a decline in liver GSH to a level between one
half and two thirds of normal after a 48 hour fast. These
experiments suggest a half-life longer than two days. One
possible explanation for this long half-life under starved
conditions is that the normal dietary amino acid input is
partly replaced by protein catabolism. However, given the
normal rate of GSH efflux, a 48 hour half-life would
Table 3: Normal model blood concentrations (μM)
Cys = 186 Gly = 221 Glut = 60.4 GSH = 12.7 GSSG = 0.48
Table 2: Normal model cytosolic reaction velocities (μM/hr)
Folate Cycle Methionine cycle Transsulfuration
VMTD = -103 VMATI = 125 VCBS = 103
VMTCH = -103 VMATIII = 80.5 VCTGL = 103
VFTS = 552 VGNMT = 61.6 VGCS = 1250
VFTD = 72.8 VDNMT = 144 VGS = 1250
VART = 188 VSAHH = 205 VGPX = 312
VPGT = 188 VMS = 40.2 VGR = 269
VSHMT = 12.1 VBHMT = 61.9
VNE = 58.6
VTS = 133
VDHFR = 133
VMTHFR = 40.3Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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require that catabolism replace 94% of daily dietary input,
which seems improbably high.
An alternative explanation, which could potentially
explain both sets of experiments, is that exported GSH is
broken down into constituent amino acids in the blood
that are rapidly reimported into the liver cells. Indeed, it is
known that the enzyme γ-glutamyltranspeptidase (GGT)
on the external cell membrane initiates this process
(called the γ-glutamyl cycle) [12,50,51]. In our model the
computed value of GSH transport out of the cell (Table 4)
is VcGSHb = 1152 and the rates of Cys, Gly, and Glut import
are also high (Table 4), although we assume that 10% per
hour of the amino acids in the blood are lost to non-liver
cells and an additional 25% of Cys is lost by conversion to
cystine. Figure 2 shows the cytosolic concentration of
GSH in our model liver cells for 10 hours after the concen-
tration of the enzyme GCS was set to zero. The computed
half life of GSH is 3 hours.
Figure 3 shows the concentration of GSH and other
metabolites in our model liver cell during a fasting exper-
iment over a 48 hour period. We assume that during fast-
ing, protein catabolism supplies 1/3 of the normal amino
acid input. The GSH concentration declines slowly over
the 48 hour period to about 50% of normal and the rate
of GSH export declines to 67% of normal consistent with
the experiments reported in [33]. Thus the rapid reimport
hypothesis explains both sets of data. Other metabolites
show interesting changes during the fast. The methionine
cycle metabolites adjust very rapidly to the decreased
methionine input reaching new steady states within a few
hours. However, the metabolites in the GSH synthesis,
export and reimport pathway decline very slowly, achiev-
ing their new steady states in 4–5 days (data not shown).
Mosharov et al. [26] studied the role of the transsulfura-
tion pathway in GSH synthesis. When they blocked CTGL
they observed that that the intracellular GSH concentra-
tion dropped to a new steady state of approximately 42%
of control in about 24 hours. They concluded that approx-
imately half of GSH is derived via the transsulfuration
pathway. Our methionine input is computed to be 103
μM/h consistent with experimental measurements
[26,52] and our cysteine input into the system is 70 μM/
h. If we remove the methionine input in the model, the
GSH concentration declines to a new steady-state 47% of
normal. On the other hand, if we remove cysteine input
the GSH concentration declines to a new steady-state 68%
of normal. These model results support the interpretation
in [26] that methionine and cysteine inputs contribute
equivalently to GSH synthesis. We remark that one would
not expect the contributions of the two metabolites to
GSH synthesis to be strictly proportional to their inputs
since they are used in other reactions and the system is
highly non-linear.
C. Inhibition of GCS
It is well known [27,41] that GSH is a competitive inhibi-
tor against glutamate of GCS, the enzyme that catalyzes
the synthesis of glutamyl-cysteine. This inhibition can
naturally be thought of as product inhibition, one step
removed. As glutathione rises it indirectly inhibits its own
synthesis and as glutathione falls the inhibition is
released. Figure 4 shows that this inhibition has the effect
that is expected at steady state. As sulfur amino acid input
rises, so does glutathione concentration but not as fast as
it would if the inhibition were not present. At low sulfur
amino acid concentrations the effect is small. Thus the pri-
mary effect of the inhibition is to prevent excess accumu-
lation of GSH. Such accumulation would sequester more
amino acids, would increase transport out of the cell up to
saturation, and would therefore increase the loss of
cysteine to cystine in the blood.
GSH half life after GCS is blocked Figure 2
GSH half life after GCS is blocked. When GSH synthesis 
is stopped the model intracellular GSH concentration 
declines rapidly with a half life of approximately 3 hours.
Table 4: Normal model net transport velocities (μM/hr)
VoCysb = 70.0 VoGlyb = 630.0 VoGlutb = 273
VbCysc = 1213 VbGlyc = 1816 VbMetc = 103 VbSerc = 787 VbGlutc = 1475
VcGSHb = 1152 VcGSSGb = 36.3
VbGSHo = 8.9 VbGSSGo = 3.6 VbCyso = 64.9 VbGlyo = 22.1 VbGluto = 6.0Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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D. Stability of GSH under large input fluctuations
Hepatocytes are seldom at steady state [21] because they
receive large protein inputs during and shortly after meals
and relatively little protein input between meals. How do
these daily fluctuations affect the intracellular and blood
glutathione pools? To investigate this question, we varied
the amino acid input (cysteine, glycine, glutamate,
methionine, and serine) throughout the day and used the
model to compute the time courses of all the concentra-
tions in the model, and all the velocities. Let A denote the
daily average input of a particular amino acid. While fast-
ing (for example, from 12 midnight until 7 am), we
assume that the input is (0.25)A. From 7 am to 10 am, we
assume that the input is (1.75)A corresponding to break-
fast, followed by two hours of fasting. Then, from 12 noon
until 3 pm we assume that the input is (1.75)A corre-
sponding to lunch, followed by three hours of fasting and
then an input of (3.25)A for three hours corresponding to
dinner. The complete daily input profile is shown in Fig-
ure 5A.
Panel B of Figure 5 shows that the fluctuations in methio-
nine input cause very large fluctuations in SAM but only
modest fluctuations in intracellular methionine concen-
tration, as suggested by the early methionine loading
Effect of GSH feedback inhibition Figure 4
Effect of GSH feedback inhibition. The GSH concentra-
tion is plotted as a function of the intracellular concentration 
of sulfur amino acids. The solid curve shows the GSH con-
centration when the inhibition of GCS is included in the 
model. The dashed curve shows the GSH concentration 
when the inhibition by GSH is removed.
GSH and GSH transport under fasting conditions Figure 3
GSH and GSH transport under fasting conditions. After three hours, the inputs of cysteine, methionine, glycine, gluta-
mate, and serine are reduced to 1/3 of normal. The intracellular GSH + GSSG concentration declines slowly over the 48 hour 
period to about 50% of normal and the rate of GSH export declines to 67% of normal consistent with the experiments 
reported in [33]. The cytosolic and blood cysteine concentrations decline proportionally to GSH. The methionine cycle metab-
olites and fluxes equilibrate rapidly.Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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experiments of Finkelstein and co-workers [53,54]. Cor-
rales et al. [55] have suggested that the relative stability of
methionine is due to the complicated kinetics of MAT-I
and MAT-III and we have confirmed this by model exper-
iments [56]. Panel B also shows that the intracellular GSH
concentration (divided by 100 for graphing purposes)
also remains stable throughout the day.
Panel C of Figure 5 shows that the velocity of the CBS reac-
tion tracks the methionine input as expected, but that the
velocity of the GS reaction by which GSH is synthesized
has milder fluctuations. These smaller fluctuations are a
result of the inhibition of the GCS reaction by GSH (see
Section C). In addition, the intracellular GSH pool is nor-
mally very large (6591 μM in our model, see Table 1).
Both of these effects contribute to the impressive stability
of the GSH concentration, seen in Panel B, in the face of
large fluctuations in amino acid input. Note that the
velocity of the DNA methylation reaction (DNMT in
Panel C) is also quite stable despite the fact that its sub-
strate, SAM, is undergoing very large fluctuations. It is
understood that this is a result of long-range allosteric
interactions between the methionine cycle and the folate
cycle [18].
Panel D of Figure 5 shows that homocysteine undergoes
large fluctuations in synchrony with the methionine input
as expected. 5mTHF also fluctuates but in the opposite
direction from homocysteine for two reasons. First, when
methionine input rises dramatically, so does [SAM] and
SAM inhibits MTHFR. Secondly, when homocysteine
rises, it drives the MS reaction faster, which reduces
5mTHF. Finally, the blood concentration of GSH remains
completely stable despite the large transient amino acid
input fluctuations.
The Stability of the glutathione pools in the face of input fluctuations Figure 5
The Stability of the glutathione pools in the face of input fluctuations. Panel A shows the amino acid input to the 
model hepatocytes throughout a 24 hour day. The input is 25% of the mean while fasting, 175% of the mean for three hours 
after breakfast and lunch, and 325% of the mean for three hours after dinner. For discussion, see the text. Panel B shows mod-
erate variations in methionine concentrations and extremely large swings in SAM concentration, but GSH concentration 
remains stable. Panel C shows that the velocity of the CBS reaction varies dramatically, but the velocity of the GS reaction, 
which synthesizes glutathione, shows milder variation. As expected, the long range allosteric reactions between the folate cycle 
and the methionine cycle stabilize the velocity of the DNA methylation reaction (vDNMT). Panel D shows that there are large 
variations in 5mTHF and Hcy throughout the day, but the GSH concentration in the blood remains stable.Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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E. Oxidative Stress
In our model, oxidative stress is represented by the con-
centration of H2O2. When H2O2 increases there are several
effects on one-carbon metabolism. First, the increased
concentration of H2O2  inhibits the enzymes MS and
BHMT and activates the enzymes CBS and GCS [25,26].
Secondly, the balance of GSH and GSSG is shifted toward
GSSG via the GPX and GR reactions. This affects the
upstream metabolites in the methionine and transsulfura-
tion pathways because GSSG inhibits the enzymes MAT-I
and MAT-III [57,58]. All of these influences are in the
model; for details, see Additional File 1. The response to
oxidative stress in the model is surprisingly complex; see
Figure 6.
Under moderate oxidative stress there are moderate
increases on blood and cytosolic GSH and blood cysteine,
while cytosolic cysteine and the [GSH]/[GSSG] ratio
decline. Cytosolic GSH increases because oxidative stress
activates CBS and GCS increasing the flux through the
GCS and GS reactions and simultaneously lowering the
cytosolic cysteine concentration. Since cytosolic GSH
increases, the export out of the cell will also increase thus
raising the blood GSH and blood cysteine concentrations.
The elevated H2O2 concentration drives the balance in the
GPX and GR reactions towards GSSG thus lowering the
[GSH]/[GSSG] ratio. Under high oxidative stress this bal-
ance is shifted even further towards GSSG and this has
consequences for overall cysteine balance.
In the model cytosolic GSH has three fates: it is trans-
ported into the blood, there is a net flux to GSSG, and
0.2% is removed per hour corresponding to detoxification
reactions and excretion into the bile. Likewise, cytosolic
GSSG has two fates: it is transported into the blood, and
10% is removed per hour corresponding to excretion into
the bile. Of course, removal of one GSH or GSSG results
in the removal of one or two cysteines, respectively. At
normal steady state concentrations the cysteine lost by
these two mechanisms are about equal. However, as the
oxidative stress increases and the balance between GSH
and GSSG shifts toward GSSG, more cysteines are lost
from the system per hour. At moderate oxidative stress
this effect small. However, with high or chronic levels of
oxidative stress this effect gets much larger and the loss of
cysteines is quite large. This causes the rate of the GS reac-
tion to come back down to normal despite the upregula-
tion of CBS and GCS and cause the steady concentrations
of cytosolic GSH and the blood concentrations of GSH
and cysteine to decline below normal; see Figure 6.
E. The Metabolic Profile of Down Syndrome
Down syndrome is a complex metabolic and genetic dis-
order whose root cause, trisomy 21, is an extra copy of
chromosome 21 [59]. Down syndrome is not rare; it
occurs in approximately 1 out every 700–800 live births
[60]. Children with Down syndrome have abnormal met-
abolic profiles and show increased incidence of a large
number of serious diseases including leukemia and diabe-
tes [61]. In most cases, it is not understood whether these
diseases are caused by the extra chromosome, the altered
metabolic profile, or both.
To investigate the metabolite profile of Down syndrome
using the model, we began by increasing by 50% the Vmax
of CBS, since the gene for CBS is on chromosome 21 and
is expressed at 150% of normal. The first column of Table
5 shows the average percent change in the levels of six
plasma metabolites in 42 Down patients compared to con-
trols (taken from [13]). The second column shows the
percentage change in these metabolites in the model
when the Vmax of CBS is increased by 50%. Note that the
intracellular concentrations of Hcy, SAM, SAH, and Met
all change in the same direction as seen clinically. We
would not expect a close match to the clinically observed
percentage changes because we are comparing intracellu-
lar model changes to blood measurements. The increased
dosage of CBS has almost no effect on the model plasma
concentrations of bCys and bGSH. Thus these changes
must come from some other effect of chromosome 21 tri-
somy.
It is known that Down patients suffer from mild to mod-
erate oxidative stress due to the overexpression of the Cu-
Zn superoxide dismutase (SOD) gene that is also located
on chromosome 21 [62]. Column 3 in Table 5 shows the
effects on metabolite concentrations when the H2O2 con-
Effect of oxidative stress Figure 6
Effect of oxidative stress. The curves show the effect on 
the steady-state values of cysteine and GSH in the cytosol 
and the blood, the rate of GSH synthesis by GS, and the 
cytosolic [GSH]/[GSSG] ratio as H2O2 concentration is 
raised from normal (0.01 μM) to 0.05 μM.Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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centration (normally 0.01 μM) is increased to 0.025 μM
in addition to the increased dosage of CBS. The methio-
nine cycle metabolites are further reduced compounding
the effects of trisomy 21. Blood cysteine increases substan-
tially and blood GSH declines modestly. The reason for
the increase in [bCys] under mild oxidative stress is dis-
cussed in Section E.
A number of clinical observations suggest that Down
patients may have a functional folate deficiency despite
having normal plasma levels of folate and vitamin B12
[13]. The model results support the discussion in [13] of
why this is so. The increased expression of CBS lowers the
concentration of Hcy and therefore lowers the rate of the
MS reaction. Thus, folate builds up in the form of 5mTHF
(the "methyl trap") and there is less folate in the forms
CH2-THF and 10f-THF that are the substrates for thymi-
dylate and purine synthesis, respectively. Indeed, the last
three rows of Table 5 show that the up-regulation of CBS
has exactly this effect and that the addition of oxidative
stress makes the effect much stronger.
F. The Metabolic Profile of Autism
Autism is a complex neurodevelopmental disorder whose
cause is unknown and which is diagnosed solely on
behavioral criteria [63]. The incidence of autism has been
increasing and is now thought to be present in ~1 in 150
children in the United States [64]. Numerous studies sug-
gest that both genetic and environmental influences are
important in the development of autism [65-67]. Some
studies have identified metabolic deficiencies in autistic
children [14], and it has recently been shown that there is
a characteristic metabolic profile in many autistic children
involving disturbances in methionine and glutathione
metabolism [14,15]. The first and second columns in
Table 6 show the changes in blood levels of various
metabolites in autistic children compared to normal
patients in two different clinical studies [14,15].
One of the working hypotheses in [14,15] is that autistic
children have a self-perpetuating cycle of inflammation
and oxidative stress. Indeed, it is reported that autistic
children have increased levels of brain and gut inflamma-
tion [68,69]. The fact that blood GSH levels in autistic
children were down 32–46% and the blood GSH/GSSG
ratio was down 48–66% is also consistent with this
hypothesis (Table 6). Oxidative stress is represented in the
model by the concentration of H2O2. The H2O2 concen-
tration drives the redox balance in the cell from GSH
toward GSSG (see Figure 1) and the increased concentra-
tions of H2O2 and GSSG can modulate many enzymes in
one-carbon metabolism (see Section E). In Column 3 of
Table 6 we show the result of a substantial increase of oxi-
dative stress in the model to 5 times the normal level. The
model intracellular concentrations of Hcy, Met, and SAM
all fall dramatically corresponding to the clinically
observed declines in their plasma concentrations. The
model concentration of bGSH and the bGSH/bGSSG ratio
both decline in the plasma similarly to the degree of
decline seen in the autistic patients in the clinic. Finally,
we note that severe oxidative stress causes a "methyl trap"
such that the model concentration of 5mTHF more than
doubles. There are several underlying reasons for the
methyl trap: the concentration of Hcy drops, oxidative
stress inhibits MS, and the drop in [SAM] releases the inhi-
bition of MTHFR, which drives more folate towards the
5mTHF form.
There is one apparent discrepancy between the model
results in column 3 (Table 6) and the clinical results in
columns 1 and 2. The model intracellular concentration
of SAH declines under severe oxidative stress while in
patients the average concentration of SAH in the blood
Table 5: Down syndrome: Clinical and model metabolic changes (%)*
substrate clinical change CBS × 1.5 H2O2 normal CBS × 1.5 H2O2 × 2.5
Hcy -24 -29 -35
Met -47 -5 -15
bCys 15 0.2 13
bGSH -14 0.2 -2
SAM -18 -21 -48
SAH -22 -26 -49
Cys -- 2 -55
5mTHF -- 29 117
CH2-THF -- -14 -51
10fTHF -- -7 -34
* Clinical data in Column 1 are % changes in blood levels of metabolites averaged over 42 Down patients compared to 38 control patients [13]. 
Columns 2 and 3 show % changes in model values. In columns 2 and 3, bCys and bGSH indicate model blood concentrations, and the other 
metabolites are intracellular. Column 2 shows the effect of increasing the dosage of CBS by a factor of 1.5. Column 3 shows the effect of increased 
CBS combined with moderate oxidative stress. For discussion, see the text.Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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went up 24–49%. It is reported in [14] that the plasma
adenosine concentration was significantly elevated on the
average in autistic children compared to controls, though
both populations showed very large standard deviations.
The observed plasma increase in adenosine could be due
to a decrease in adenosine deaminase activity, inhibition
of adenosine kinase, or an increase in 5-nucleotidase, all
of which can occur in the presence of oxidative stress [70-
72]. In our model, intracellular adenosine concentration
is a constant. When we raised the constant by a factor of
5, we obtained the results in column 4 (Table 6). The met-
abolic profile is very similar to that in column 3 except
that now the intracellular SAH concentration does not
decline but instead increases by 24% in line with the clin-
ical data.
Finally, we note that the model predicts modest decreases
in the rate of the DNA methylation reaction (vDNMT)
and this is consistent with the reported global DNA
hypomethylation seen in autistic children [73]. The
decrease in reaction rate is caused by the decrease in
[SAM] and the increase in [SAH], which inhibits DNMT.
Discussion
We have expanded our previous model of one-carbon
metabolism to include the transsulfuration pathway, the
synthesis and export of glutathione, and its breakdown in
and export from the blood. This has enabled us to investi-
gate a number of specific problems about glutathione
metabolism from the experimental and clinical literature.
We have shown that the glutathione pool is very insensi-
tive to the large variations inacute amino acid input
caused by daily meals. In some cases we have been able to
give causal explanations for observed experimental phe-
nomena and we are able to test the quantitative effects of
various allosteric inhibitions and excitations. Finally, we
used to model to show how the observed metabolic pro-
file of Down syndrome could arise from trisomy 21 and
moderate oxidative stress and how the observed meta-
bolic profile of autism patients could arise from high oxi-
dative stress and increased adenosine concentration.
In a series of papers [34-36], Ookhtens and colleagues
showed that the half-life of glutathione in the liver was
quite low, approximately 2–3 hours, consistent with the
result of Lauterburg [47]. On the other hand, the same
group showed in [33] that glutathione has a half-life of
approximately two days in the livers of fasted rats. In Sec-
tion B we confirmed that there is no contradiction
between these results. In the first case, GSH synthesis is
blocked, so the rapid export of GSH makes the GSH con-
centration decline rapidly. In the second case, even
though the rats are fasted, the rapid reuptake of cysteine,
glycine, and glutamate by the liver cells insures that the
synthesis of GSH declines relatively slowly and therefore
the observed half-life is long. Finally, the model results
support the conclusions of Mosharov et al. [26] that both
cysteine and methionine contribute approximately
equally to GSH synthesis in the liver. This is true even
though GSH is exported rapidly and cysteine is reim-
ported rapidly compared to the methionine input.
Lu proposes in [12] that the high glutathione concentra-
tion in hepatocytes is a storage mechanism for cysteine.
But what is the reason for the rapid cycling, i.e. fast export
of GSH, breakdown by GGT, and fast reimport of
cysteine? This is a futile cycle that requires a lot of energy.
A reasonable hypothesis is that the rapid cycling allows
the liver to respond quickly to the glutathione require-
ments of other tissues. This hypothesis is consistent with
the idea that glutathione is a mechanism for cysteine stor-
age [12], but also helps explain the reason for the γ-
Table 6: Autism: Clinical and model metabolic changes (%)*
substrate clinical change 1 clinical change 2 H2O2 × 5 H2O2 × 5 adenosine up
Hcy -5 -9 -19 -39
Met -26 -39 -20 -26
bCys -20 -19 -9 -9
bGSH -32 -46 -35 -34
SAM -10 -22 -61 -22
SAH 24 49 -54 24
bGSH/bGSSG -48 -66 -88 -88
5mTHF -- -- 154 144
vDNMT -- -- -6 -10
*Clinical data in columns 1 and 2 are average changes in blood levels of metabolites in autistic children compared to control patients [14, 15]. 
Columns 3 and 4 show % changes in model values. In columns 3 and 4 bCys, bGSH and bGSSG indicate model blood concentrations, and the other 
metabolites are intracellular. vDNMT is the velocity of the DNA methylation reaction (μM/hr). Column 3 shows the effect of severe oxidative 
stress that is a factor of 5 higher than normal. Column 4 shows the effect of adding increased adenosine concentration to the oxidative stress. For 
discussion, see the text.Theoretical Biology and Medical Modelling 2008, 5:8 http://www.tbiomed.com/content/5/1/8
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glutamyl cycle and the reason for the short half-life of
hepatic GSH.
Cell metabolism is very complicated and the same sub-
strate is often used in many different reactions. As a result
the response function of a metabolite or a reaction veloc-
ity to changes in a parameter or input may be nonlinear
and non-monotone. For example, in Section E we showed
that moderate oxidative stress causes blood GSH and
blood cysteine to rise, but severe oxidative stress causes
blood GSH and blood cysteine to fall. This increase at low
oxidative stress is due to the stimulation of CBS and GCS
that increases GSH synthesis and concentration, and
therefore the rate of export. At high or chronic oxidative
stress, however, the model suggests that the balance shifts
towards GSSG, and removal of cysteine in the form of
GSSG dominates, resulting in a decline in cysteine.
There is increasing evidence that oxidative stress plays a
role in the development of autism [74]. The metabolic
profile of autistic patients has been shown to be abnormal
with elevated biomarkers that indicate chronic oxidative
stress and evidence that GSH synthesis may be insufficient
to maintain redox homeostasis [14,15]. Likewise, the
overexpression of SOD is children with Down syndrome
leads to a reduction of GSH and an increase in oxidative
stress [13]. In our model oxidative stress is represented by
an elevated level of H2O2 which induces many changes in
one-carbon metabolism and the transsulfuration path-
way. H2O2 stimulates CBS and GCS and inhibits MS and
BHMT. In addition H2O2 drives the GSH/GSSG balance
towards GSSG, which inhibits MAT I and MAT III. We
have found that, in our model, oxidative stress alone can
produce some but not all the metabolic characteristics of
Down syndrome and autism. However, the addition of
trisomy 21 in the first case, and raised adenosine in the
second, brings the profiles much closer to those observed
in patients with Down syndrome and autism, respectively.
Cellular amino acid concentrations are increased by feed-
ing and protein degradation and decreased by protein
synthesis, growth and use in one-carbon metabolism.
During early growth (until about the second year after
birth), about 10–20% of the amino acid pool is used in
growth and is thus not available for GSH synthesis and
one-carbon metabolism [75-77]. This would be expected
to have an effect on the rates amino-acid-requiring proc-
esses of one-carbon metabolism and glutathione synthe-
sis. We have found, by simulation, that if we reduce the
amino acid input into the system by 15%, the concentra-
tion of GSH and the synthesis rate of GSH are proportion-
ally diminished, but there is little effect on the DNA
methylation reaction, while reactions in the folate cycle
are reduced by 2–9%. This reduction in GSH synthesis
may contribute to excessive oxidative stress in infants.
Calculations with the model show that blood concentra-
tions do not necessarily reflect intracellular concentra-
tions of metabolites. For example, the increased dosage of
CBS and GCS in our simulation of Down syndrome
causes the intracellular concentration of cysteine to
decline while the blood concentration increases. This
shows that care must be taken in interpreting blood meas-
urements, and that ideally one would like to conduct
experiments in which both intracellular and extracellular
concentrations are measured. By contrast, we found in the
model (simulations not shown) that the blood concentra-
tions of GSH and GSSG track the intracellular concentra-
tions.
The purpose of this model was to study the properties of
intracellular glutathione metabolism, in particular the
effects of oxidative stress and trisomy 21. Of course intra-
cellular glutathione metabolism is affected by the import
of amino acids and the export and removal of GSH and
GSSG. We therefore needed include a blood compartment
and to keep track of bCys, bGly, bGSH, bGSSG and bGlut.
The kinetics of the contents of the blood compartment are
complicated because GSH and its component amino acids
in the blood interact with the kidney, the brain, and other
tissues. These important interactions are beyond the scope
of this initial investigation, but will be incorporated in
future studies.
This model provides a tool, different from laboratory
experimentation, that can be used to experiment with
one-carbon and glutathione metabolism. By using the
tool, it is possible to quickly and easily test hypotheses,
evaluate new ideas, and give causal explanations for what
is seen in the clinic and the lab. In this spirit, the authors
welcome questions, suggestions, and hypotheses to test
from clinicians and experimentalists.
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cleotide transferase; BHMT: betaine-homocysteine meth-
yltransferase; CBS: cystathionine β-synthase; CTGL: β-
cystathionase; DHFR: dihydrofolate reductase; DMGD:
dimethylglycine dehydrogenase; DNMT: DNA-methyl-
transferase; FTD: 10-formyltetrahydrofolate dehydroge-
nase; FTS: 10-formyltetrahydrofolate synthase; GCS: γ-
glutamylcysteine synthetase; GDC: glycine decarboxylase
(glycine cleavage system); GNMT: glycine N-methyltrans-
ferase; GPX: glutathione peroxidase; GR: glutathione
reductase; GS: glutathione synthetase; MAT-I: methionine
adenosyl transferase I; MAT-III: methionine adenosyl
transferase III; MS: methionine synthase; MTCH: 5,10-
methenyltetrahydrofolate cyclohydrolase; MTD: 5,10-
methylenetetrahydrofolate dehydrogenase; MTHFR: 5,10-
methylenetetrahydrofolate reductase; NE: non-enzymatic
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malase; SAAH: S-adenosylhomocysteine hydrolase; SDH:
sarcosine dehydrogenase; SHMT: serinehydroxymethyl-
transferase; TS: thymidylate synthase; VX: velocity of the
reaction catalyzed by X; Metabolites. 10f-THF: 10-
formyltetrahydrofolate; 5mTHF: 5-methyltetrahydro-
folate; AICAR: P-ribosyl-5-amino-4-imidazole carboxam-
ide; CH = THF: 5-10-methenyltetrahydrofolate; CH2-THF:
5-10-methylenetetrahydrofolate; Cys: cysteine Cysta cys-
tathionine; DHF: dihydrofolate; DMG: dimethylglycine;
dTMP: deoxythymidine monophosphate; dUMP: deoxyu-
ridine monophophate; GAR: glycinamide ribonucleotide;
Glut: glutamate; Glut:Cys glutamyl-cysteine; Gly: glycine.
GSH: glutathione; GSSG: glutathione disulfide; H2C= O:
formaldehyde. H2O2 hydrogen peroxide. HCOOH for-
mate. Hcy homocysteine. Met methionine. NADPH nico-
tinamide adenine dinucleotide phosphate; SAH: S-
adenosylhomocysteine; SAM: S-adenosylmethionine;
Sarc: sarcosine; Ser: serine; THF: tetrahydrofolate
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